Jeffrey S. Sherman is recorded as CFO at Neogenomics Inc (NEO) since December 7, 2022. Neogenomics Inc reported in an 8-K filed January 12, 2026 that Jeffrey S. Sherman retired as Chief Financial Officer, effective April 14, 2026. Neogenomics Inc reported in an 8-K filed December 6, 2022 that Jeffrey S. Sherman was appointed Chief Financial Officer, effective December 7, 2022. The proxy statement of Neogenomics Inc reports total compensation of $3,482,409 for Jeffrey S. Sherman in fiscal 2024, including a base salary of $540,346. Disclosed compensation is on record for 3 fiscal years. Jeffrey S. Sherman has spoken on 1 earnings call across 1 company, most recently for Neogenomics Inc on July 29, 2025. Neogenomics Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Neogenomics Inc includes Chris Smith (CEO and Board Member), Christopher Smith (CEO and Board Member), Tony Zook (CEO, Chairman and Board Member) and 7 others.
“Mr. Sherman is expected to serve as the Company's Executive Vice President, Finance through April 14, 2026, the effective date of his retirement.”
Neogenomics Inc Form 8-K, filed January 12, 2026
· Read the filing
“On December 5, 2022, the Company appointed Jeffrey S. Sherman, age 57, as Chief Financial Officer of the Company, effective December 7, 2022 (the "Effective Date").”
Neogenomics Inc Form 8-K, filed December 6, 2022
· Read the filing
Jeffrey S. Sherman on recent calls
“In the second quarter, total revenue growth accelerated compared to Q1, rising 10% year-over-year to $181 million. Total clinical revenue also continued to show double-digit growth, increasing by 16% from the previous year.”
